Advanced BioDesign
Overcoming tumor drug resistance.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €14.3m | Growth Equity VC | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (85 %) | 679 % | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (40220 %) | (7397 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (3772 %) | (29079 %) | (5921 %) | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Advanced BioDesign is a biotechnology company specializing in the development of ALDH1 enzyme inhibitors for cancer treatment. Operating in the biosciences sector, the company collaborates with academic and industrial partners globally. Founded in 2010, Advanced BioDesign focuses on business development, innovation management, and industrial property. The company has successfully raised funds from private investors, strengthening its board and scientific committee. Its lead product, ABD 3001, targets acute myeloid leukemia (AML) and entered clinical trials in early 2023, showing a promising safety profile. Another product, ABD 0171, is being developed for solid tumors and has shown enhanced efficacy when combined with anti-PD1 therapies. Additionally, the company has developed a predictive and prognostic test to identify and stratify patients based on ALDH enzyme activity. Advanced BioDesign generates revenue through the development and commercialization of its proprietary cancer therapies and diagnostic tests.
Keywords: ALDH1 inhibitors, cancer metabolism, immunomodulation, acute myeloid leukemia, solid tumors, clinical trials, biotechnology, predictive tests, prognostic tests, innovation management.